Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says

-- Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.

Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.

A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.

The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.

Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.

Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.

RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.

Price: $152.47, Change: $+1.33, Percent Change: +0.88%

中國聯合網路通訊公司第一季獲利下降18%

中國連網通訊（SHA:600050）週三在上海證券交易所發布的公告顯示，該公司第一季歸屬於股東的淨利潤年減18%至21.4億元人民幣，即每股0.068元人民幣。去年同期，該公司歸屬於股東的淨利為26.1億元人民幣，即每股0.083元。營業收入較去年同期下降1%至1,028億元人民幣，去年同期為1,034億元。該公司股價在早盤交易下跌2%。

$SHA:600050

韓國3月份生產者價格上漲4.1%。

根據韓國央行週三公佈的初步數據，韓國3月生產者物價指數（PPI）較去年同期上漲4.1%，創下自2023年2月以來的最快漲幅。除電力、瓦斯、水和廢棄物處理成本當月下降1.1%外，其他所有類別的PPI均出現上漲，推動了PPI年漲。數據顯示，農產品、林業及海鮮、製造業及服務業的PPI分別上漲0.5%、5.9%及3.1%。數據顯示，3月PPI月增1.6%。

$^KOSDAQ$^KS11

金屬粉末製品公司稱，3月季度粉末產品營收幾乎翻番，股價下跌4%。

金屬粉末製品公司（ASX：MPW）週三向澳洲證券交易所提交的文件顯示，該公司3月季度的粉末收入比上季幾乎翻了一番，毛利率維持在50%左右。該公司在該季度共收到35份訂單，其中包括18份回頭客訂單和17份首次交付訂單。該公司表示，其「下一代1號」項目進展順利，符合預算，首批粉末已成功生產，並朝著100噸的設計產能逐步提升。該公司持有1310萬澳元現金，無任何債務。該公司股價在周三的交易中下跌了4%。

$ASX:MPW

相關文章

中國聯合網路通訊公司第一季獲利下降18%

韓國3月份生產者價格上漲4.1%。

金屬粉末製品公司稱，3月季度粉末產品營收幾乎翻番，股價下跌4%。